How long does Kymriah’s effect persist?
Kymriah (tisagenlecleucel) is designed as a one-time CAR T-cell treatment, and its clinical “persistence” is typically reported as how long the CAR T cells remain detectable and/or how durable responses last.
What does “persistence” mean in Kymriah studies?
In CAR T trials, persistence usually refers to the duration CAR T cells can be detected in the patient after infusion (often described using measures like CAR T-cell expansion and time to loss of detectability). The question asks for the duration, but no specific persistence duration is provided in the information available here.
What data do you need to answer the question precisely?
To give a specific duration (for example, “median persistence of X months” or “still detectable in Y% at Z months”), the exact source is needed, such as:
- the indication (e.g., pediatric/young adult B-ALL vs adult DLBCL),
- the study/trial publication (e.g., a specific phase 1/2 report),
- the persistence endpoint definition used in that report.
If you share which disease setting and/or the study you mean, I can give the persistence duration from that source.
Quick clarification to avoid a mismatched answer
Are you asking about:
- how long CAR T cells remain detectable (cell persistence), or
- how long remissions last (clinical durability)?
Sources cited: none (no provided source material for persistence duration).